The EPS miss and accelerating cash burn (SG&A up 76% YoY) are concerning, but the pending CVS Caremark formulary decision (target July 1) is a key catalyst that could drive significant revenue acceleration. Monitor the early June update on CVS approval — if positive, it could offset the bearish quarter. The stock may trade on the CVS news rather than the EPS miss.
Price Chart
Executive Summary
ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7M, beating the $22.1M consensus, with neffy U.S. net product revenue of $17.5M. Net loss was $60.6M ($0.61 per share), wider than the consensus EPS of -$0.54, driven by $72.2M in SG&A expenses for neffy commercialization. The EPS miss of 13% vs consensus is the primary negative surprise, but the company highlighted strong commercial momentum, a pending CVS Caremark formulary decision, and a cash runway through cash-flow break-even.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $22.7M vs consensus $22.1M (beat)
- neffy U.S. net product revenue $17.5M
- Net loss $60.6M ($0.61 per share) vs consensus -$0.54 (13% miss)
- SG&A expenses surged to $72.2M from $41.1M YoY, driving wider loss
- Cash, equivalents, and short-term investments $201.0M as of March 31, 2026
- CVS Caremark formulary proposal in final approval stages; update expected early June
- Sales force expanded from 106 to 148 representatives
- Phase 2b CSU trial interim data readout on track for Q4 2026
Financial Impact
EPS miss of 13% vs consensus ($0.61 actual vs $0.54 estimate) and net loss widened 79% YoY to $60.6M
Risk Factors
- CVS Caremark formulary decision may be delayed or denied, limiting commercial access
- Cash burn rate of ~$60M/quarter implies ~3.3 quarters of runway, raising potential need for financing
- EPS miss and widening losses could pressure the stock near-term
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295658 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | 144 | $4.29 $4.18 | ▲ +2.56% | ▲ +3.09% | $4.03 (+6.06%) |
Sep 28, 2026 28d ago | Court Ruling | $4.40 $4.31 | ▼ −2.05% | ▼ −1.84% | $4.03 (−8.41%) |
Sep 16, 2026 5w ago | Court Ruling | $4.15 $4.11 | ▼ −0.96% | ▼ −0.84% | $4.03 (−2.89%) |
Aug 3, 2026 12w ago | Press Release | $5.46 $5.32 | ▼ −2.56% | ▼ −4.37% | $4.03 (−26.19%) |
Jul 17, 2026 14w ago | Court Ruling | $6.44 $6.36 | ▼ −1.24% | ▼ −2.08% | $4.03 (−37.42%) |
Jul 7, 2026 15w ago | 8-K | $8.10 $7.88 | ▼ −2.72% | ▼ −3.56% | $4.03 (−50.25%) |
Jun 12, 2026 19w ago | Insider Cluster | $9.81 $9.70 | ▼ −1.12% | ▼ −0.53% | $4.03 (−58.92%) |
May 15, 2026 23w ago | 8-K | $7.43 $7.30 | ▼ −1.68% | ▼ −1.62% | $4.03 (−45.72%) |
May 15, 2026 23w ago | Press Release | $7.43 $7.30 | ▲ +1.68% | ▲ +1.62% | $4.03 (+45.72%) |
May 13, 2026 23w ago | 8-K | $8.01 $7.94 | ▼ −0.87% | ▼ −1.65% | $4.03 (−49.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers